2025-09-06 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the information you provided, formatted as a report in English:

## TransMedics Group Inc. (TMDX) Stock Analysis

**TransMedics Group Inc. (TMDX) is a medical technology company focused on preserving and assessing organs for transplantation.**

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 202.64%
*   **VOO Cumulative Return:** 72.87%
*   **Spread (Current):** 137.2
*   **Spread (Relative):** 55.9 (Indicates the current spread is in the upper-middle range of its historical fluctuation relative to VOO.)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period considered. The relative spread of 55.9 suggests that while the outperformance is substantial, there's still room for potential fluctuation based on historical data.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2019-2021  | -4.0%   | 63.4% | -52.0%  | 0.0    | 0.7    |
| 2020-2022  | 140.0%  | 68.3% | 138.0%  | 0.1    | 2.1    |
| 2021-2023  | 95.0%   | 69.4% | 77.0%   | 0.2    | 2.7    |
| 2022-2024  | 147.0%  | 82.8% | 121.0%  | 0.2    | 2.1    |
| 2023-2025  | 84.0%   | 82.8% | 31.0%   | 0.5    | 3.5    |

**Analysis:**

*   **CAGR:**  Shows very strong growth in recent periods (2020-2024), but the CAGR has fluctuated.
*   **MDD:**  High Maximum Drawdown values across all periods indicate significant volatility and risk.
*   **Alpha:** Consistently high positive alpha figures indicate that TMDX has generated returns above what would be expected based on market movements alone.
*   **Beta:** Beta values are low, suggesting TMDX's price is not highly correlated with the market (S&P 500). Beta is increasing over time.
*   **Cap(B):** Market capitalization has grown over the time period.

### 2. Recent Stock Price Movement

*   **Current Price:** \$104.01
*   **Previous Close:** \$104.05
*   **Change:** -\$0.04 (slight decrease)
*   **5-Day Moving Average:** \$107.76
*   **20-Day Moving Average:** \$118.71
*   **60-Day Moving Average:** \$121.04

**Analysis:** TMDX's current price is below all three moving averages, indicating a recent downtrend. The fact that the 5-day moving average is closest to the current price suggests a potential short-term stabilization, but further observation is needed. The small change from the previous close does not signal a dramatic event.

### 3. Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3322 (Low Risk)
*   **RSI:** 11.33 (Oversold)
*   **PPO:** -1.74 (Bearish)
*   **Hybrid Signal:** cash_60%_Sell 0.1% of holdings (1 shares - Caution - MRI:0.32)
*   **Delta_Previous_Relative_Divergence (20-day):** -2.1 (Indicates short-term decline)
*   **Expected Return:** 77.5% (Long-term, relative to S&P 500)

**Analysis:**

*   The low RSI indicates the stock is heavily oversold and could be due for a bounce, but doesn't guarantee it.
*   The negative PPO confirms the bearish momentum.
*   The Hybrid Signal suggests caution, recommending a reduction in holdings and increasing cash position.
*   The negative change in relative divergence reinforces the short-term downward trend.
*   The low MRI indicates an attractive buying opportunity.
*   Despite the current bearish signals, the significantly high expected return suggests strong long-term potential.

### 4. Recent News & Significant Events

*   **[2025-09-04] Stifel Initiates TransMedics Group at Neutral With \$115 Price Target:** A neutral rating suggests a hold or wait-and-see approach.
*   **[2025-08-29] Reasons to Retain TransMedics Stock in Your Portfolio for Now (Zacks):** Indicates a positive outlook, suggesting the stock is worth holding.
*   **[2025-08-29] Why Is TransMedics (TMDX) Down 1.9% Since Last Earnings Report? (Zacks):** Explores potential reasons for recent underperformance, which could be due to market corrections or unmet expectations.
*   **[2025-08-28] What TransMedics Group (TMDX)'s Upward 2025 Earnings Revisions Mean For Shareholders (Simply Wall St.):** Positive news suggesting increased confidence in the company's future earnings.
*   **[2025-08-25] TransMedics to Present at Upcoming September Investor Conferences:** Provides opportunities for the company to share its vision and strategy.
*   **[2025-08-25] Terumo to buy OrganOx for \$1.5B to enter transplant field:**  This is relevant because it shows increased industry interest and investment in organ preservation technology, which could indirectly benefit TransMedics.

**Analysis:** The news is mixed, with some positive long-term indicators (earnings revisions, hold recommendation) offset by neutral ratings and explanations for recent price drops. The acquisition of OrganOx highlights the growing interest in the organ transplant field.

#### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Opinions:** 8 analysts
*   **Target Price:** Average: \$138.88, High: \$170.00, Low: \$114.00

**Analysis:**

*   The analyst consensus is a "Buy," indicating a generally positive outlook on the stock.
*   The average target price of \$138.88 suggests potential upside from the current price.
*   **Recent Rating Changes:** Not Provided in the given content.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 예상 EPS |
|------------|------|----------|
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

**Analysis:** TransMedics has consistently beaten EPS estimates in the most recent quarters, which is a positive sign for the company's financial performance. The Q2 2025 EPS was significantly higher than expected.

### 6. Financial Information

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | \$0.16B    | 61.38%        |
| 2025-03-31 | \$0.14B    | 61.47%        |
| 2024-12-31 | \$0.12B    | 59.21%        |
| 2024-09-30 | \$0.11B    | 55.94%        |
| 2024-06-30 | \$0.11B    | 60.59%        |

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-06-30 | \$0.32B    | 10.97% |
| 2025-03-31 | \$0.27B    | 9.64%  |
| 2024-12-31 | \$0.23B    | 3.00%  |
| 2024-09-30 | \$0.21B    | 2.01%  |
| 2024-06-30 | \$0.19B    | 6.42%  |

**Analysis:**

*   **Revenue:** Shows a clear upward trend, indicating strong growth.
*   **Profit Margin:** Consistently high profit margins suggest efficient operations.
*   **Equity:** Increasing equity indicates a strengthening financial position.
*   **ROE:** Return on Equity has been increasing in recent quarters, which is a positive sign of profitability.

### 7. Overall Summary & Conclusion

TransMedics Group Inc. (TMDX) presents a mixed picture. The company has shown significant outperformance compared to the S&P 500, strong revenue growth, high profit margins, and positive earnings surprises. Analyst ratings are generally positive, with an average target price suggesting potential upside. However, recent price action indicates a short-term downtrend, and technical indicators like RSI and PPO suggest the stock may be oversold. The Hybrid Signal recommends caution. The high Maximum Drawdown values and recent news headlines also highlight the stock's volatility.

**Recommendation:**

Given the conflicting signals, a balanced approach is warranted. While the long-term outlook appears positive based on financial performance and analyst consensus, the short-term risks are evident. Investors may consider a cautious approach, such as dollar-cost averaging, to build a position over time, while closely monitoring the stock's price action and news flow. Investors should also be aware of the company's volatility.
